继与雷诺达成深度合作后，吉利的全球化布局再传新动向。近日，路透社援引多位知情人士消息 称，吉利与福特正就潜在合作展开磋商，双方谈判的核心聚焦于产能共享与技术协同两大维度。一方 面，吉利计划借助福特在欧洲的现有工厂，生产面向欧洲市场的车型；另一方面，双方也在积极探讨车 辆技术共享框架，重点涵盖自动驾驶等关键领域。截至目前，双方尚未就合作细节达成最终协议。 这一合作思路，与吉利此前同雷诺的合作模式高度契合，更清晰勾勒出中国车企全球化的共性路 径。从早年"市场换技术"的被动跟随，到如今"技术促合作"的主动引领，以吉利为代表的中国车企，正 以合作共赢为核心纽带，走出一条独具特色的全球化道路，悄然重塑全球汽车产业的竞争格局。 以合作破局，依托产能共享突破贸易壁垒，是中国车企全球化布局的关键一步。当前，全球贸易保 护主义思潮持续蔓延，区域关税壁垒不断加剧，单纯依靠产品出口的传统模式，已难以适配海外市场的 长远发展需求。本地化生产成为中国车企扎根海外、实现可持续发展的核心前提，但独立建厂不仅耗资 巨大，且建设周期漫长，因此，与当地拥有成熟产能的车企开展合作，便成为高效可行的破局之举。 这种"借船出海"的产能协同模式，在吉利 ...

2月26日早盘，港股创新药板块震荡下行，100%创新药研发标的——港股通创新药ETF（520880）场内 价格现跌逾1%，场内宽幅溢价，低吸资金或较活跃。 成份股方面，药捷安康-B领涨逾5%，联邦制药、康方生物涨逾1%。下跌方面，百济神州重挫3%，康哲 药业、石四药集团、石药集团跌逾2%。 港股通创新药ETF（520880）被动跟踪恒生港股通创新药精选指数，该指数前十大权重股分别为石药集 团、百济神州、康方生物、中国生物制药、信达生物、翰森制药、三生制药、科伦博泰生物-B、康哲药 业、荣昌生物。 数据来源于沪深交易所、公开资料等。 风险提示：以上产品由基金管理人发行与管理，代销机构不承担产品的投资、兑付和风险管理责任。投 资人应当认真阅读《基金合同》、《招募说明书》、《基金产品资料概要》等基金法律文件，了解基金 的风险收益特征，选择与自身风险承受能力相适应的产品。基金过往业绩并不预示其未来表现，基金投 资须谨慎！销售机构（包括基金管理人直销机构和其他销售机构）根据相关法律法规对本基金进行风险 评价，投资者应及时关注基金管理人出具的适当性意见，各销售机构关于适当性的意见不必然一致，且 基金销售机构所出具的基金产 ...

业内普遍认为作为华大智造布局北美的核心载体，CGI的剥离并非简单的资产处置，而是公司全球化战略的一次"换道"。 此前1月底华大智造曾披露2025年业绩预告，预计2025年归母净利润将亏损2.21亿元～2.73亿元，与2024年相比同比亏损将大幅收窄54.56%～ 63.22%，同期扣非净利润则为亏损3.2亿元～3.97亿元，同比亦收窄39.18%～50.67%。 而在最新公告中，华大智造表示，预计此次出售CGI获得的约5000万美元对价收入，将为其带来显著的直接收益和持续的现金流改善。 基因测序设备龙头华大智造的全球化战略迎来重大调整。在节前刚宣布拟3.66亿收购两家公司后，节后开工的第一天就又披露了一项出售 海外子公司的交易。 2月24日，公司公告披露，拟以5000万美元对价，将旗下美国全资子公司Complete Genomics（下称"CGI"）100%股权，转让给瑞士生物技术企 业Swiss Rockets。与此同时，双方进一步扩大合作边界，华大智造将其核心技术——光学测序仪StandardMPS在美国、加拿大地区的独占授 权，一并打包授予后者，同步配套给予该区域内相关通用测序技术的普通许可。 而值得注 ...

21世纪经济报道记者唐唯珂 基因测序设备龙头华大智造的全球化战略迎来重大调整。在节前刚宣布拟3.66亿收购两家公司后，节后 开工的第一天就又披露了一项出售海外子公司的交易。 2月24日，公司公告披露，拟以5000万美元对价，将旗下美国全资子公司Complete Genomics（下 称"CGI"）100%股权，转让给瑞士生物技术企业Swiss Rockets。与此同时，双方进一步扩大合作边界， 华大智造将其核心技术——光学测序仪StandardMPS在美国、加拿大地区的独占授权，一并打包授予后 者，同步配套给予该区域内相关通用测序技术的普通许可。 业内普遍认为作为华大智造布局北美的核心载体，CGI的剥离并非简单的资产处置，而是公司全球化战 略的一次"换道"。 此前1月底华大智造曾披露2025年业绩预告，预计2025年归母净利润将亏损2.21亿元～2.73亿元，与2024 年相比同比亏损将大幅收窄54.56%～63.22%，同期扣非净利润则为亏损3.2亿元～3.97亿元，同比亦收 窄39.18%～50.67%。 公开信息显示，CGI成立于2006年，2013年被华大集团收购，主要聚焦于基因测序技术研发与相关产品 ...

本报讯 2月23日晚间，深圳华大智造科技股份有限公司（以下简称"华大智造"）发布公告，拟以约5000 万美元出售子公司Complete Genomics，Inc.（以下简称"CGI"）100%股权，并升级对交易方的测序技术 授权，新增StandardMPS技术在美国、加拿大地区的独占许可，同时配套授予该区域内该技术领域通用 测序技术的普通许可。 此次交易授权范围仅限StandardMPS产品领域，华大智造全资子公司MGI US LLC仍可自主拓展半导体 自发光测序仪、实验室智能自动化产品、纳米孔单分子测序仪及时空组学产品等多元产品线。同时， CGI将205项覆盖全技术链条的专利、技术秘密及商标，永久性、免费且不可撤销地授权给华大智造全 资子公司，让公司掌握核心技术控制权。 本次交易是华大智造战略、业务与财务层面的综合考量结果，若顺利推进，将推动中国生命科学企业 从"产品输出"迈向"技术输出"，同时改善财务表现、进阶全球化战略。 财务层面，交易将带来多重利好。现金收益方面，除5000万美元股权对价外，公司已收到2025年11月到 账的2000万美元技术授权首付款，还有2000万美元里程碑付款待收，将直接增厚现金 ...

Investment Rating - The report indicates a strong growth outlook for the company, with projected net profit for 2025 expected to reach between 1.1 billion to 1.2 billion, representing a year-on-year growth of 79%-95% [1] Core Insights - The company's growth is primarily driven by a significant improvement in its domestic insulin business, which saw a revenue increase of 45.6% in the first three quarters of 2025, characterized by both volume and price increases [2][4] - The successful selection of all six products in the 2024 national procurement for insulin has led to a more than 30% increase in procurement volume compared to the previous round, providing a substantial boost in sales certainty [4] - The company's gross margin has stabilized above 73% over the past two years, indicating effective cost control and product structure optimization, allowing it to convert procurement pressure into market share and profit [4][6] Domestic Business Performance - The company has captured a 30% market share in the third-generation insulin procurement, positioning itself as the leading domestic player, second only to Novo Nordisk, amidst a trend of domestic products replacing imports [6] - The company’s products are now available in over 40,000 medical institutions, with rapid growth particularly in grassroots markets [6] International Expansion - International sales revenue reached 350 million in the first three quarters of 2025, marking a 45.5% year-on-year increase [7] - A significant 10-year technology transfer and supply agreement with Brazil, valued at no less than 3 billion, positions the company as the sole approved solution for Brazil's national public health system [7][9] - The company is transitioning from merely exporting products to a more sophisticated model of technology output, which includes local production technology transfer and talent development [9] Research and Development Focus - The company is heavily investing in R&D, with R&D expenses accounting for 13.4% of revenue in the first three quarters of 2025 [10] - Key products in development include GZR4 (ultra-long-acting insulin), which is in Phase III clinical trials and aims to revolutionize patient treatment habits, and GZR18 (GLP-1 dual-week formulation), which has received FDA approval and shows promising weight loss results [11][12] - The company is also advancing GZR101 (premixed dual insulin) into Phase II clinical trials, aiming to provide more convenient treatment options [12] - The successful launch of either GZR4 or GZR18 could elevate the company from an "insulin expert" to a "comprehensive solution provider for metabolic diseases" [14]

Core Viewpoint - Ganli Pharmaceutical (603087.SH) is expected to achieve a net profit of 1.1 to 1.2 billion yuan in 2025, representing a year-on-year growth of 79% to 95%, driven by a significant recovery in its insulin business amidst procurement pressures [3][4]. Group 1: Core Business Growth - The growth of Ganli is primarily attributed to the substantial improvement in its domestic insulin business, with revenue increasing by 45.6% in the first three quarters of 2025, characterized by both volume and price increases [4][6]. - A key turning point was the successful participation in the 2024 national insulin procurement, where all six products were selected, leading to a more than 30% increase in procurement volume compared to the previous round [6]. - The company's gross margin has stabilized above 73% over the past two years, recovering from a significant drop post-2022 procurement, indicating effective cost control and product structure optimization [6][9]. Group 2: Market Position and Competition - Ganli's share of the third-generation insulin procurement volume has reached 30%, making it the leading domestic player, second only to Novo Nordisk, as foreign market shares decline [9]. - The company has expanded its product coverage to over 40,000 medical institutions, with rapid growth in grassroots markets [9]. Group 3: International Expansion - International sales revenue for Ganli reached 350 million yuan in the first three quarters of 2025, marking a 45.5% year-on-year increase [10]. - A significant breakthrough was a 10-year technical transfer and supply agreement with Brazil, valued at no less than 3 billion yuan, making Ganli the only approved solution for Brazil's national public health system [10][11]. - The company's strategy involves not just drug exports but also high-level "technology output," including local production technology transfer and talent training [11][12]. Group 4: Research and Development Focus - Ganli is heavily investing in research and development, with R&D expenses accounting for 13.4% of revenue in the first three quarters of 2025 [13]. - The company is targeting the next frontier in diabetes treatment with products like GZR4 (ultra-long-acting insulin) and GZR18 (GLP-1 dual-week formulation), both of which are in advanced clinical stages and have significant market potential [15][16]. - Ganli aims to transition from being an "insulin expert" to a "comprehensive solution provider for metabolic diseases" upon successful product launches [16].

Core Insights - Dongfeng Fengxing has officially launched its first KD factory in Cairo, Egypt, marking a significant step in its global strategy "Chengfeng Shuangqing 2030" with six models covering fuel, pure electric, and hybrid technologies [1][3] Group 1: Strategic Importance of Egypt - Egypt serves as a strategic hub for Dongfeng Fengxing's expansion into Africa due to its geographical location, market potential, and supportive policies [5] - The country connects North Africa, the Middle East, and Europe, reducing logistics and time costs for regional operations [5] - Egypt's large population and rapid urbanization create a high-potential automotive market, driven by increasing family travel and demand for smart, electric vehicles [5] Group 2: Localized Integration - Dongfeng Fengxing has achieved a threefold breakthrough in local market integration through technology localization, product adaptation, and ecosystem development [6] - The KD factory employs flexible production lines to accommodate various powertrains, addressing the uneven infrastructure in Africa [8] - Collaboration with Huawei aims to introduce advanced technologies tailored to local conditions, enhancing the smart and electric vehicle integration [8] Group 3: Sales and Growth Performance - In 2025, despite industry challenges, Dongfeng Fengxing's total sales reached 147,647 units, a 22.9% increase year-on-year, significantly outperforming the market average [3] - Passenger vehicle sales grew by 13.5% to 96,534 units, while overseas sales surged tenfold over five years, with exports exceeding 53,000 units, a 32.7% increase [3] Group 4: Future Expansion Plans - The establishment of the factory is seen as a starting point for a three-phase strategy to expand from North Africa to the entire African market [11] - The short-term focus will be on consolidating the Egyptian base and replicating success in Algeria, Morocco, and Tunisia from 2025 to 2027 [11] - The mid-term strategy from 2028 to 2030 will extend into East and West Africa, adapting products to local infrastructure conditions [11] Group 5: Industry Impact - Dongfeng Fengxing's entry into Egypt represents a shift in the Chinese automotive industry's approach to international markets, moving beyond simple trade to technology sharing and local ecosystem development [13] - The collaboration with local partners and the introduction of advanced technologies position Chinese brands as key players in Africa's transition to electric and smart mobility [13]

Core Viewpoint - The bus industry represents China's automotive manufacturing sector becoming a global leader in technology output, with overseas market contributions expected to recreate a market equivalent to China in the next 3-5 years [4][12]. Group 1: Driving Factors for the Bus Industry - **Timing**: Aligns with the national strategy of "China's Special Valuation," with buses being a strong practitioner of the "Belt and Road" initiative, leveraging over a decade of overseas experience [4][12]. - **Geographical Advantage**: The technology and products of Chinese buses are at a world-class level, leading in new energy buses and competitive in traditional buses regarding cost-effectiveness and service [4][12]. - **Human Factors**: The end of the price war in the domestic market is expected to resonate positively, with demand recovering due to tourism and public transport renewal needs, potentially returning to 2019 levels [4][12]. Group 2: Profitability Outlook - The bus industry is expected to achieve new high profitability due to the absence of price wars, an oligopolistic market structure, better net profit margins in overseas markets, and declining lithium carbonate costs [5][16]. Group 3: Market Capitalization Potential - The short-term goal is to challenge the market capitalization peak from the last industry boom (2015-2017), while the long-term goal is to establish a new ceiling, witnessing the emergence of a true global bus leader [6][16]. Group 4: Investment Recommendations - **Yutong Bus**: Identified as a "model student" with high growth and dividend attributes, with projected net profits of 4.94 billion, 5.92 billion, and 7.03 billion yuan for 2025-2027, reflecting year-on-year growth of 20%, 20%, and 19% respectively, maintaining a "buy" rating [7][14]. - **King Long Automobile**: Considered the "fastest improving student," with significant profit elasticity, projected net profits of 440 million, 640 million, and 830 million yuan for 2025-2027, with year-on-year growth of 182%, 45%, and 28%, also maintaining a "buy" rating [8][14]. Group 5: Industry Data Summary - In December 2025, the overall production of the bus industry in China was 59,000 units, with year-on-year and month-on-month increases of 3.94% and 8.56% respectively [19][20]. - The wholesale volume for December 2025 was 64,000 units, with year-on-year and month-on-month increases of 5.49% and 20.11% respectively [19][20]. - The terminal sales volume for December 2025 was 62,400 units, with year-on-year and month-on-month increases of 5.93% and 28.10% respectively [22].

Group 1 - The core viewpoint of the article highlights Yutong Bus's strategy in overseas markets, which combines direct sales and distribution channels to enhance its global presence [1] - The company has established a comprehensive overseas sales and service network, covering six major regions: Europe, America, Asia-Pacific, CIS, Middle East, and Africa through over 70 subsidiaries, offices, and distribution partners [1] - Yutong Bus has upgraded its business model from "product export" to "technology export and brand licensing" by engaging in localized cooperation through KD assembly in countries such as Kazakhstan, Pakistan, Ethiopia, and Malaysia [1]